Skip to Content
Know what to ask with our GIST Doctor Discussion Guide

Iodixanol Pregnancy and Breastfeeding Warnings

Iodixanol is also known as: Visipaque

Iodixanol Pregnancy Warnings

Reproduction studies in rats and rabbits at higher than the maximum human recommended dose have not revealed evidence of impaired fertility or harm to the fetus. There are no controlled data in human pregnancy. AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus and its use is considered essential. AU TGA pregnancy category: B1 US FDA pregnancy category: B Comments: -Check thyroid function in neonates during the first week of life, following administration of iodinated contrast agents to the mother during pregnancy. -Repeat testing of thyroid function at 2 to 6 weeks of age, particularly in low birth weight or premature newborn.

See references

Iodixanol Breastfeeding Warnings

Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -The effects in the nursing infant are unknown. -Because the amount of contrast medium excreted in human breast milk appears to be low and only minimal amounts are absorbed by the intestine, some experts recommend continuing breast feeding normally.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide